Gland Pharma receives USFDA approval for new injection
Key Highlights
Gland Pharma received USFDA approval for its Methylprednisolone Acetate Injectable Suspension, a product with $214 million in recent US sales.
Gland Pharma received approval from the United States Food and Drug Administration for its Methylprednisolone Acetate Injectable Suspension. The company secured this clearance for both single-dose and multiple-dose vials of the medication. This product serves as a bioequivalent and therapeutically equivalent version of the reference listed drug currently sold by Pfizer Inc.
The USFDA approved the Abbreviated New Drug Application for various strengths of the injectable suspension. Data from IQVIA indicate that the US market for this injection reached roughly $214 million during the year concluding in August 2026. The company intends to market this product for treating a wide range of conditions including allergic states, endocrine disorders, and respiratory diseases.
Gland Pharma operates by developing, manufacturing, and marketing complex injectables. The firm primarily conducts its business through a business-to-business model across multiple international markets. This approval allows the company to expand its portfolio of injectable products available for the United States healthcare sector.
Based on company and agency reports. For information only; not investment advice.